Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program

Archives of Internal Medicine

Volumn 158, Issue 7, 1998, Pages 741-751

  Savage, Peter J ^a   Pressel, Sara L ^a   David Curb, J ^a   Schron, Eleanor B ^a   Applegate, William B ^a   Black, Henry R ^a   Cohen, Jerome ^a   Davis, Barry R ^a   Frost, Philip ^a   Smith, W ^a   Gonzalez, Nelly ^a   Guthrie, Gordon P ^a   Oberman, Albert ^a   Rutan, Gale ^a   Probstfreld, Jeffrey L ^a   Stamler, Jeremiah ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIURETIC AGENT; GLUCOSE; LIPID; PLACEBO; POTASSIUM ION; RESERPINE; URIC ACID;

ADULT; AGED; AGING; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 0032513534     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.7.741     Document Type: Article

References (39)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
2. Weber MA, Laragh JH, for The Fifth Report of Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Hypertension: steps forward and steps backward. Arch Intern Med. 1993;153:149-152.
3. Lewis PJ, Kohner EM, Petrie A, Dolleery CT. Deterioration in glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet. 1976;1:564-566.
4. Perez-Sabel E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid and potassium metabolism. Am Heart J. 1983;106:245-251.
5. Ames RP. Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: lipid alterations and glucose intolerance. Am Heart J. 1983;106:1207-1214.
6. Weinberger MH. Antihypertensive therapy and lipids: paradoxical influences on cardiovascular disease risk. Am J Med. 1986;80:64-70.
7. The Working Group on Hypertension in Diabetes. Statement on hypertension in diabetes mellitus: final report. Arch Intern Med. 1987;147:830-842.
8. Frishman WH. Beta adrenergic receptor blockers: adverse effects and drug interactions. Hypertension. 1988;11(suppl 2):21-29.
9. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 1988;115:640-656.
10. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension. 1988;11(suppl 2):16-20.
11. Dall'Aglio E, Strata A, Reaven GM. Abnormal lipid metabolism in treated hypertensive patients with non-insulin dependent diabetes mellitus. Am J Med. 1988;84:899-903.
12. Chait A. Effects of antihypertensive agents on serum lipids and lipoproteins. Am J Med. 1989;86(suppl 1B):5-7.
13. Fhu MMT, Sheu WHH, Shen DC, Wu DA, Chen YDI, Reaven GM. Metabolic effects of diuretic and beta blocker treatment of hypertension in patients with non-insulin dependent diabetes mellitus. Am J Hypertens. 1990;3:387-390.
14. Stein PP, Black HR. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care. 1991;14:425-448.
15. The National High Blood Pressure Education Program Working Group. The National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
16. Bengtsson C, Blohme G, Lapidis L, et al. Do antihypertensive drugs precipitate diabetes? BMJ. 1984;289.1495-1497.
17. Skarfors ET, Lithell HO, Selinus I, Alber H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ. 1989;298:1147-1151.
18. Goodkin G. Mortality factors in diabetes. J Occup Environ Med. 1975;17:716-721.
19. Harris MI, Madden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years. Diabetes. 1987;36:523-534.
20. Curb JD, Lee M, Jensen J, Applegate W. Systolic Hypertension in the Elderly Program (SHEP), part IV: baseline medical history findings. Hypertension. 1991;17 (suppl 2):35-61.
21. Borhani NO, Applegate WB, Cutler JA, et al. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample, I: rationale and design. Hypertension. 1991;17(suppl 2):2-15.
22. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1988;41:1197-1208.
23. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
24. Curb JD, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
25. Labarthe DR, Blaufox MD, Smith WM, et al. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample, II: baseline blood pressure and pulse rate measurements. Hypertension. 1991;17 (suppl 2):62-76.
26. Hall WD, Davis BR, Frost P, et al. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample, VII: baseline laboratory characteristics. Hypertension. 1991;17(suppl 2):102-122.
27. Petrovitch H, Byington R, Bailey G, et al. Systolic Hypertension in the Elderly Program (SHEP): baseline characteristics of the randomized sample, II: screening and recruitment. Hypertension. 1991;17(suppl 2):16-23.
28. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
30. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979;59:8-13.
31. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA. 1993;269:505-510.
32. Brand FN, McGee DL, Kannel WB, Stokes J III, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121:11-18.
33. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the MRFIT Intervention Trial Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
34. Helderman JH, Elahi D, Anderson DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106-111.
35. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1565-1607.
36. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
37. Hoes AW, Grobbee DE, Lubsen J, Manin't Veld AJ, van der Does E, Hofman A. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995;123:481-487.
38. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
39. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensi ve and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.